Human platelet activation is associated with an increase in dimeric PKM2 formation. (A) Western blot of PKM2 in human and murine platelets. (B) The left panel shows a representative image of the nonreducing (native) western blot of PKM2 dimer and tetramer formation in human platelets pretreated with vehicle or ML265 and stimulated with convulxin (100 ng/mL) or thrombin (0.1 U/mL). The red box represents PKM2 dimers. The right panel presents the dimer/tetramer ratio densitometry analysis. Values are mean ± SEM, n = 4 individual donors per group. Two-way ANOVA followed by Tukey’s multiple comparisons test. (C) Lactate production in human platelets with convulxin (100 ng/mL). Values are mean ± SEM, n = 4 individual donors per group. One-way ANOVA followed by Tukey’s multiple comparisons test. (D) Effect of PKM2 inhibition on glucose uptake. Values are mean ± SEM, n = 3 individual donors per group. *P < .05 vs resting platelets, ^†P < .05 vs activated platelets (vehicle). Two-way ANOVA followed by Tukey’s multiple comparisons test. RP, resting platelets.